2,211
Views
17
CrossRef citations to date
0
Altmetric
Original Articles

Development of bicalutamide-loaded PLGA nanoparticles: preparation, characterization and in-vitro evaluation for the treatment of prostate cancer

, &
Pages 944-954 | Received 02 Feb 2016, Accepted 26 May 2016, Published online: 21 Jun 2016

References

  • Adams ML, Lavasanifar A, Kwon GS. 2003. Amphiphilic block copolymers for drug delivery. J Pharm Sci. 92:1343–1355.
  • Aulton ME. 1988. Pharmaceutics: The Science of Dosage Form Design. 4th ed. London, UK: Churchill Livingstone, pp. 69–86.
  • Bolourchian N, Mahboobian MM, Dadashzadeh S. 2013. The effect of PEG molecular weights on dissolution behavior of simvastatin in solid dispersions. Iran J Pharm Res. 12:11–20.
  • Boury F, Ivanova T. Panaiotov, et al. 1995. Dynamic properties of poly (D, L-lactide-co-glycolide) and Polyvinyl alcohol monolayers at the air/water and dichloromethane air/water interfaces. J. Colloid Interface Sci. 169:380–392.
  • Budhian A, Siegel SJ, Winey KI. 2005. Production of haloperidol-loaded PLGA nanoparticles for extended controlled drug release of haloperidol. J Microencapsul. 22:773–785.
  • Clarke GS. 1994. The validation of analytical methods for drug substances and drug products in UK pharmaceutical laboratories. J Pharm Biomed Anal. 12:643–652.
  • Cui Z, Hsu CH, Mumper RJ. 2003. Physical characterization and macrophage cell uptake of mannan-coated nanoparticles. Drug Dev Ind Pharm. 29:689–700.
  • Dash S, Murthy PN, Nath L, Chowdhury P. 2010. Kinetic modeling on drug release from controlled drug delivery systems. Acta Pol Pharm. 67:217–223.
  • Dhas NL, Ige PP, Kudarha RR. 2015. Design, optimization and in-vitro study of folic acid conjugated-chitosan functionalized PLGA nanoparticle for delivery of bicalutamide in prostate cancer. Powder Tech. 283:234–245.
  • Erbetta CD, Alves RJ, Resende JM, de Souza Freitas RF, de Sousa RG. 2012. Synthesis and characterization of poly (D, L-lactide-co-glycolide) Copolymer. J Biomater Nanobiotechnol. 3:208–210.
  • Foster KA, Yazdanian M, Audus KL. 2001. Microparticulate uptake mechanisms of in-vitro cell culture models of the respiratory epithelium. J Pharm Pharmacol. 53:57–66.
  • Hariharan M, Price JC. 2002. Solvent, emulisifier and drug concentration factors in poly-(D-L-Lacticacid) microspheres containing hexamethylmelamine. J Microencap. 19:95–109.
  • Herrero-Vanrell R, Ramirez L, Fernandez-Carballido A, Refojo MF. 2000. Biodegradable PLGA microspheres loaded with ganciclovir for intraocular administration. Encapsulation technique, in vitro release profiles, and sterilization process. Pharm Res. 17:1323–1328.
  • Hoskins C, Thoo-Lin PK, Cheng WP. 2012. A review on comb-shaped amphiphilic polymers for hydrophobic drug solubilization. Ther Deliv. 3:59–79.
  • Hsu HC, Chien CS. 1994. Validation of analytical methods: a simple model for HPLC assay methods. Food Drug Anal. 2:161–176.
  • Huang X, Brazel CS. 2001. On the importance and mechanisms of burst release in matrix-controlled drug delivery systems. J Control Release. 73:121–136.
  • Iler RK. 1975. Coacervates of polyvinyl alcohol and colloidal silica. J Colloid Interface Sci. 51:388–393.
  • Jain S, Mittal AK, Jain R, Mahajan R, Singh D. 2010. Cyclosporin A loaded PLGA nanoparticle: preparation, optimization, in-vitro characterization and stability studies. Curr Nanosci. 6:422–431.
  • Jeffery H, Davis SS, O'Hagan DT. 1991. The preparation and characterisation of poly(lactide-co-glycolide) microparticles. I: oil-in-water emulsion solvent evaporation. Int J Pharm. 77:169–175.
  • Kasperczyk J. 1996. Microstructural analysis of poly[(l, l-lactide)-co-(glycolide)] by 1H and 13C NMR spectroscopy. Polymer. 37:201–203.
  • Kohler N, Sun C, Wang J, Zhang M. 2005. Methotrexate-modified super paramagnetic nanoparticles and their intracellular uptake into human cancer cells. Langmuir. 21:8858–8864.
  • Kranz H, Ubrich N, Maincent P, Bodmeier P. 2000. Physicomechanical properties of biodegradable poly(D,L-lactide) and poly(D,L-lactide-co-glycolide) films in the dry and wet states. J Pharm Sci. 89:1558–1566.
  • Lawrence MJ, Rees GD. 2000. Microemulsion-based media as novel drug delivery systems. Adv Drug Deliv Rev. 45:89–121.
  • Lee SC, Oh JT, Jang MH, Chung SI. 1999. Quantitative analysis of polyvinyl alcohol on the surface of poly(D, L-lactide-co-glycolide) microparticles prepared by solvent evaporation method: effect of particle size and PVA concentration. J Control Release. 59:123–132.
  • Li C, Le Y, Chen JF. 2011. Formation of bicalutamide nanodispersion for dissolution rate enhancement. Int J Pharm. 404:257–263.
  • Mainardes RM, Evangelista RC. 2005. PLGA nanoparticles containing praziquantel: effect of formulation variables on size distribution. Int J Pharm. 290:137–144.
  • Maji R, Dey NS, Satapathy BS, Mukherjee B, Mondal S. 2014. Preparation and characterization of Tamoxifen citrate loaded nanoparticles for breast cancer therapy. Int J Nanomed. 9:3107–3118.
  • Masiello D, Cheng S, Bubley GJ, Lu ML, Balk SP. 2002. Bicalutamide functions as an androgen receptor antagonist by assembly of a transcriptionally inactive receptor. J Biol Chem. 277:26321–26326.
  • McGowen R, Biliran H, Sager R, Sheng S. 2000. The surface of prostate carcinoma DU145 cells mediates the inhibition of urokinase-type plasminogen activator by maspin. Cancer Res. 60:4771–4778.
  • Mo Y, Lim LY. 2004. Mechanism study of the uptake of wheat germ agglutinin-conjugated PLGA nanoparticles by A549 cells. J Pharm Sci. 93:20–28.
  • Müller RH. 1991. Colloidal Carriers for Controlled Drug Delivery and Targeting: Modification, Characterization, and In Vivo Distribution. Stuttgart Boca Raton: Wissenschaftliche Verlagsgesellschaft, CRC Press. pp. 38–44.
  • Murakami H, Kobayashi M, Takeuchi H, Kawashima Y. 1999. Preperation of poly (D, L-lactide-co-glycolide) nanoparticles by modified spontaneous emulsification solvent diffusion method. Int J Pharm. 187:143–152.
  • Murukami H, Kawashima Y, Nawa T, Hino T, Takeuchi H, Kobayashi M. 1997. Influence of the degree of hydrolization and polymerization of polyvinyl alcohol on the preperation and properties of PLGA nanoparticles. Int J Pharm. 149:43–49.
  • Nakano M. 2000. Places of emulsions in drug delivery. Adv Drug Deliv Rev. 45:1–4.
  • Okamoto R, Delansorne R, Wakimoto N, Doan NB, Akagi T, Shen M, et al. 2012. Inecalcitol, an analog of 1α,25(OH)(2) D(3), induces growth arrest of androgen-dependent prostate cancer cells. Int J Cancer. 130:2464–2473.
  • Qiu LY, Bae YH. 2006. Polymer architecture and drug delivery. Pharm Res. 23:1–30.
  • Saeedi M, Akbari J, Morteza-Semnani K, Enayati-Fard R, Sar-Reshteh-Dar S, Soleymani A. 2011. Enhancement of dissolution rate of indomethacin: using liquisolid compacts. Iran J Pharm Res. 10:25–34.
  • Sahana B, Santra K, Basu S, Mukerjee B. 2010. Development of biodegradable polymer based tamoxifen citrate loaded nanoparticles and effect of some manufacturing process parameters on them: a physicochemical and in-vitro evaluation. Int J Nanomed. 5:621–630.
  • Sahoo S, Panyam J, Prabha S, Labhasetwar V. 2002. Residual polyvinyl alcohol associated with poly (D,L-lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake. J Control Release. 82:105–114.
  • Sancheti PP, Vyas MV, Shah M, Karekar P, Pore YV. 2008. Development and characterization of bicalutamide-poloxamer F68 solid dispersion systems. Pharmazie. 63:571–575.
  • Schleich N, Sibret P, Danhier P, Ucakar B, Laurent S, Muller RN, et al. 2013. Dual anticancer drug/superparamagnetic iron oxide-loaded PLGA-based nanoparticles for cancer therapy and magnetic resonance imaging. Int J Pharm. 447:94–101.
  • Schwendener RA, Schott H. 1996. Lipophilic 1-beta-D-arabinofuranosyl cytosine derivatives in liposomal formulations for oral and parenteral antileukemic therapy in the murine L1210 leukemia model. J Cancer Res Clin Oncolo. 122:723–726.
  • Suh H, Jeong B, Liu F, Kim SW. 1998. Cellular uptake study of biodegradable nanoparticles in vascular smooth muscle cells. Pharm Res. 15:1495–1498.
  • Sun BS, Liu P, Shao FM, Miao QL. 2015. Formulation and evaluation of PLGA nanoparticles loaded capecitabine for prostate cancer. Int J Clin Exp Med. 8:19670–19681.
  • Svenson S. 2009. Dendrimers as versatile platform in drug delivery applications. Eur J Pharm Biopharm. 71:445–462.
  • Swamivelmanickam M, Gomes AR, Manavalan R, Satyanarayana D, Reddy PG. 2009. Determination and validation of UV spectrophotometric method for estimation of bicalutamide tablets. Int J ChemTech Res. 4:1189–1193.
  • Tabata Y, Ikada Y. 2005. Phagocytosis of polymer microspheres by macrophages. Adv Polymer Sci. 94:107–141.
  • Vasconcelos T, Sarmento B, Costa P. 2007. Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs. Drug Discov Today. 12:1068–1075.
  • Veiga F, Teixeira-Dias JJ, Kedzierewicz F, Sousa A, Maincent P. 1996. Inclusion complexation of tolbutamide with β-cyclodextrin and hydroxypropyl-β-cyclodextrin. Int J Pharm. 129:63–71.
  • Venkatesh DN, Baskaran M, Karri VV, Mannemala SS, Radhakrishna K, Goti S. 2015 Fabrication and in vivo evaluation of nelfinavir loaded PLGA nanoparticles for enhancing oral bioavailability and therapeutic effect. Saudi Pharm J. 23:667–674.
  • Yameen B, Choi WI, Vilos C, Swami A, Shi J, Farokhzad OC. 2014. Insight into nanoparticle cellular uptake and intracellular targeting. J Control Release. 190:485–499.
  • Yang YY, Chung TS, Ng NP. 2001. Morphology, drug distribution, and in vitro release profiles of biodegradable polymeric microspheres containing protein fabricated by double-emulsion solvent extraction/evaporation method. Biomaterials. 22:231–241.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.